{
    "clinical_study": {
        "@rank": "13130", 
        "arm_group": [
            {
                "arm_group_label": "Drug: A", 
                "arm_group_type": "Experimental", 
                "description": "Avibactam (AVI)"
            }, 
            {
                "arm_group_label": "Drug: B", 
                "arm_group_type": "Experimental", 
                "description": "Aztreonam (ATM)"
            }, 
            {
                "arm_group_label": "Drug: C", 
                "arm_group_type": "Experimental", 
                "description": "combination of Aztreonam-Avibactam (ATM-AVI)"
            }, 
            {
                "arm_group_label": "Drug: D", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomised, double-blind, 3-part study designed to investigate the safety and\n      tolerability of ATM-AVI.  The study aims to characterise the pharmacokinetics of ATM-AVI,\n      when both drugs are administered alone (ATM or AVI) and in combination (ATM-AVI), following\n      single administration, and following multiple administrations of ATM-AVI in healthy male and\n      female (females of nonchildbearing potential) volunteers both young and elderly."
        }, 
        "brief_title": "To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Complicated Infection", 
            "Bacterial Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Infection"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to\n      Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and\n      Avibactam given Alone and in Combination (ATM-AVI)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures\n\n          -  Healthy young male and female volunteers aged 18 to 45 years (inclusive) and healthy\n             elderly volunteers aged 65 or older (Part C) with suitable veins for cannulation or\n             repeated venipuncture\n\n          -  Have a body mass index (BMI) between 19 and 30 kg/m2\n\n          -  Be able to understand and willing to comply with study procedures, restrictions, and\n             requirements, as judged by the PI\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant disease or disorder which, in the opinion of\n             the PI, may either put the volunteer at risk because of participation in the study,\n             or influence the results or the volunteer's ability to participate in the study\n\n          -  History or presence of gastrointestinal, hepatic, or renal disease, or any other\n             condition known to interfere with absorption, distribution, metabolism, or excretion\n             of drugs\n\n          -  Known history of severe allergy to betalactam and/or L-arginine\n\n          -  History of severe allergy/hypersensitivity or ongoing clinically important\n             allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs\n             with a similar chemical structure or class to ATM or AVI\n\n          -  Any clinically significant illness, medical/surgical procedure, or trauma within 4\n             weeks prior to the first administration of IP"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "103", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689207", 
            "org_study_id": "D4910C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Drug: A", 
                "description": "PART A: AVI IV infusion", 
                "intervention_name": "Avibactam (AVI)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Drug: B", 
                "description": "PART A: ATM IV infusion", 
                "intervention_name": "Aztreonam (ATM)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Drug: C", 
                "description": "PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.", 
                "intervention_name": "combination of Aztreonam - Avibactam (ATM-AVI)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Drug: D", 
                "description": "PART A, PART B, PART C: matching placebo IV infusions", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aztreonam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Phase I, Safety, tolerability, healthy.", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI)", 
        "overall_official": {
            "affiliation": "Hammersmith Medicines Research Cumberland Avenue Park Royal London NW10 7EW, England Telephone: +44 020 8961 4130 Fax: +44 020 8961 8665", 
            "last_name": "Gary Peters, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "from screening visit (Day -28) to 7 days post treatment period 3 (up to Day 22)", 
                "measure": "Part A: Safety profile in terms of adverse events, ECG, blood pressure, pulse, physical examination, body temperature, haematology, clinical chemistry, coagulation, urinalysis and Direct Coombs Test.", 
                "safety_issue": "Yes", 
                "time_frame": "Part A : up to 52 days"
            }, 
            {
                "description": "from screening visit (Day -28) through follow up visit (up to Day 18)", 
                "measure": "Part B: Safety profile in terms of adverse events, ECG, blood pressure, pulse, physical examination, body temperature, haematology, clinical chemistry, coagulation, urinalysis and Direct Coombs Test.", 
                "safety_issue": "Yes", 
                "time_frame": "PART B: up to 58 days"
            }, 
            {
                "description": "from screening visit (Day -28) through follow up visit (up to Day 17)", 
                "measure": "Part C: Safety profile in terms of adverse events, ECG, blood pressure, pulse, physical examination, body temperature, haematology, clinical chemistry, coagulation, urinalysis and Direct Coombs Test.", 
                "safety_issue": "Yes", 
                "time_frame": "PART C:  up to 56 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689207"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum plasma concentration (Cmax \u00b5g/mL), maximum plasma concentration at steady state (Css,max \u00b5g/mL), time to Cmax (tmax h), time to Css,max (tss,max h), minimum plasma concentration at the end of the dosing interval on Day 1 [C(6h)min h] and at steady state (Css,min h), time of last quantifiable plasma concentration (tlast h), area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-t) \u00b5g.h/mL], from zero extrapolated to infinity (AUC \u00b5g.h/mL), during the dosing interval on Day 1 [AUC(0-6) \u00b5g.h/mL] and at steady state during the dosing interval [AUCss \u00b5g.h/mL].", 
                "measure": "Part A: PK- Plasma pharmacokinetic profile in terms of (see description) for ATM (alone) and AVI (alone) and ATM-AVI (combined) following single 1 hour IV infusions", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of each crossover period:  pre-dose, 0.25, 0.5, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 5, 6, 8, 12 and 24 hours post dose"
            }, 
            {
                "description": "Half-life (t1/2\u03bbz h),systemic plasma clearance (CL L/h), systemic plasma clearance at steady state (CLss L/h), volume of distribution at steady-state (Vss L), volume of distribution at the terminal phase (Vz L), mean residence time (MRT).", 
                "measure": "Part A: PK- Plasma pharmacokinetic profile in terms of (see description) for ATM (alone) and AVI (alone) and ATM-AVI (combined) following single 1 hour IV infusions", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of each crossover period: pre-dose, 0.25, 0.5, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 5, 6, 8, 12 and 24 hours post dose"
            }, 
            {
                "description": "Maximum plasma concentration (Cmax \u00b5g/mL), maximum plasma concentration at steady state (Css,max \u00b5g/mL), time to Cmax (tmax h), time to Css,max (tss,max h), minimum plasma concentration at the end of the dosing interval on Day 1 [C(6h)min h] and at steady state (Css,min h), time of last quantifiable plasma concentration (tlast h), area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-t) \u00b5g.h/mL], from zero extrapolated to infinity (AUC \u00b5g.h/mL), during the dosing interval on Day 1 [AUC(0-6) \u00b5g.h/mL] and at steady state during the dosing interval [AUCss \u00b5g.h/mL].", 
                "measure": "Part B: PK- Plasma pharmacokinetic profile in terms of (see description) for ATM-AVI following a single IV infusion on Day 1 and multiple IV infusions on Days 2-11", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 11: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.25,3.5, 3.75, 4, 4.5, 5, 6, 8, 12, and 24 hours.Day 4: pre dose, 1.5, 3, 4, 6"
            }, 
            {
                "description": "Half-life (t1/2\u03bbz h),systemic plasma clearance (CL L/h), systemic plasma clearance at steady state (CLss L/h), volume of distribution at steady-state (Vss L), volume of distribution at the terminal phase (Vz L), mean residence time (MRT), dose-normalized exposure parameters after single and multiple dose for AVI.", 
                "measure": "Part B: PK- Plasma pharmacokinetic profile in terms of (see description) for ATM-AVI following a single IV infusion on Day 1 and multiple IV infusions on Days 2-11", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 11: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3,3.25, 3.5,3.75,4,4.5, 5, 6, 8, 12, and 24 hours.Day 4:pre dose, 1.5,3,4,6"
            }, 
            {
                "description": "Maximum plasma concentration (Cmax \u00b5g/mL), maximum plasma concentration at steady state (Css,max \u00b5g/mL), time to Cmax (tmax h), time to Css,max (tss,max h), minimum plasma concentration at the end of the dosing interval on Day 1 [C(6h)min h] and at steady state (Css,min h), time of last quantifiable plasma concentration (tlast h), area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-t) \u00b5g.h/mL], from zero extrapolated to infinity (AUC \u00b5g.h/mL), during the dosing interval on Day 1 [AUC(0-6) \u00b5g.h/mL] and at steady state during the dosing interval [AUCss \u00b5g.h/mL].", 
                "measure": "Part C: PK- Plasma pharmacokinetic profile in terms of (see description) for ATM-AVI following multiple IV infusions Days 1-10", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 10: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.25,3.5,3.75,4,4.5,3.5, 5, 6 hours. Day 4 and 7: pre dose, 1.5,3,4,6"
            }, 
            {
                "description": "Half-life (t1/2\u03bbz h), systemic plasma clearance (CL L/h), systemic plasma clearance at steady state(CLss L/h), volume of distribution at steady-state (Vss L), volume of distribution at the terminal phase (Vz L), mean residence time (MRT).", 
                "measure": "Part C: PK- Plasma pharmacokinetic profile in terms of (see description) for ATM-AVI following multiple IV infusions Days 1-10", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 10: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.25,3.5,3.75,4,4.5, 5, 6 hours.Day 4 and 7:pre dose, 1.5,3,4.6"
            }, 
            {
                "description": "Amount of drug excreted unchanged in urine from zero to time t (Ae(0-t) mg), fraction of dose excreted unchanged in urine (fe, % dose) and renal clearance (CLR L/h).", 
                "measure": "Part A:To characterize the renal clearance of combination ATM-AVI using the following urine PK parameters (see description)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of each crossover period at pre-dose, during 0-2, 2-4, 4-6 6-8, 8-12 and 12-24h post-dose."
            }, 
            {
                "description": "Amount of drug excreted unchanged in urine from zero to time t (Ae(0-t) mg), fraction of dose excreted unchanged in urine (fe, % dose) and renal clearance (CLR L/h).", 
                "measure": "Part B: To characterize the renal clearance of combination ATM-AVI using the following urine PK parameters (see description)", 
                "safety_issue": "No", 
                "time_frame": "Day 1: pre-dose, during 0-6, 6-12 and 12-24h post-dose.  Day 11: pre-dose and during 0-6 h post-dose"
            }, 
            {
                "description": "Amount of drug excreted unchanged in urine from zero to time t (Ae(0-t) mg), fraction of dose excreted unchanged in urine (fe, % dose) and renal clearance (CLR L/h).", 
                "measure": "Part C: To characterize the renal clearance of combination ATM-AVI using the following urine PK parameters:(see description)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 10: pre-dose, during 0-6h post-dose."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}